The radiation-induced cell-death signaling pathway is activated by concurrent use of cisplatin in sequential biopsy specimens from patients with cervical cancer

Cancer Biology and Therapy

Volumn 6, Issue 6, 2007, Pages 905-911

  Iwakawa, Mayumi ^a   Ohno, Tatsuya ^a   Imadome, Kaori ^a   Nakawatari, Miyako ^a   Ishikawa, Ken Ichi ^a   Sakai, Minako ^a   Katoh, Shingo ^a   Ishikawa, Hitoshi ^a   Tsujii, Hirohiko ^a   Imai, Takashi ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Cervical cancer; Chemoradiotherapy; Microarray analysis

Indexed keywords

CD30 LIGAND; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MESSENGER RNA; PARAFFIN; PROTEIN BAX; PROTEIN P53; ANTINEOPLASTIC AGENT;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; INCIDENCE; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; UPREGULATION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; VERRUCA VULGARIS; BIOPSY; DNA MICROARRAY; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TREATMENT OUTCOME; UTERINE CERVIX TUMOR;

ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, SQUAMOUS CELL; CELL DEATH; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 41749116097     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.6.4098     Document Type: Article

References (39)

1. Ohno T, Kato S, Tsujii H. Concurrent chemoradiotherapy for cervical cancer: A review of large randomized trials and perspectives for Asian countries. Austral-Asia J Cancer 2006; 5:283-90.
2. Haie-Meder C, Fervers B, Fondrinier E, Haugh M, Lhomme C, Guastalla JP. SOR guidelines for concomitant chemoradiotherapy for patients with uterine cervical cancers: Evidence update bulletin 2004. Ann Oncol 2005; 16:1100-8.
3. Peters IIIrd WA, Liu PY, Barrett IInd RJ, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon Jr W, Alberts DS. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18:1606-13.
4. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340:1144-53.
5. Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, Rotman M, Gershenson D, Mutch DG. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004; 22:872-80.
6. Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M, Williams CJ. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 2003; 68:217-26.
7. Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, MacLean G, Souhami L, Stuart G, Tu D. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 2002; 20:966-72.
8. Vallat L, Magdelenat H, Merle-Beral H, Masdehors P, Potocki de Montalk G, Davi F, Kruhoffer M, Sabatier L, Orntoft TF, Delic J. The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. Blood 2003; 101:4598-606.
9. Snyder AR, Morgan WF. Gene expression profiling after irradiation: Clues to understanding acute and persistent responses? Cancer Metastasis Rev 2004; 23:259-68.
10. Ishikawa K, Koyama-Saegusa K, Otsuka Y, et al. Gene expression profile changes correlating with radioresistance in human cell lines. Int J Radiat Oncol Biol Phys 2006; 65:234-45.
11. Wong YF, Selvanayagam ZE, Wei N, Porter J, Vittal R, Hu R, Lin Y, Liao J, Shih JW, Cheung TH, Lo KW, Yim SF, Yip SK, Ngong DT, Siu N, Chan LK, Chan CS, Kong T, Kutlina E, McKinnon RD, Denhardt DT, Chin KV, Chung TK. Expression genomics of cervical cancer: Molecular classification and prediction of radiotherapy response by DNA microarray. Clin Cancer Res 2003; 9:5486-92.
12. Kitahara O, Katagiri T, Tsunoda T, Harima Y, Nakamura Y. Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia 2002; 4:295-303.
13. Wong YF, Sahota DS, Cheung TH, Lo KW, Yim SF, Chung TK, Chang AM, Smith DI. Gene expression pattern associated with radiotherapy sensitivity in cervical cancer. Cancer J 2006; 12:189-93.
14. Ohno T, Nakano T, Niibe Y, et al. Bax protein expression correlates with radiation-induced apoptosis in radiation therapy for cervical carcinoma. Cancer 1998; 83:103-10.
15. Sato H, Ishida S, Toda K, Matsuda R, Hayashi Y, Shigetaka M, Fukuda M, Wakamatsu Y, Itai A. New approaches to mechanism analysis for drug discovery using DNA microarray data combined with KeyMolnet. Curr Drug Discov Technol 2005; 2:89-98.
16. Ishikawa H, Mitsuhashi N, Sakurai H, Maebayashi K, Niibe H. The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with stage IIIB cervical carcinoma treated with radiation therapy alone. Cancer 2001; 91:80-9.
17. Tomizawa Y, Kohno T, Fujita T, Kiyama M, Saito R, Noguchi M, Matsuno Y, Hirohashi S, Yamaguchi N, Nakajima T, Yokota J. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene 1999; 18:1007-14.
18. Narayan G, Pulido HA, Koul S, Lu XY, Harris CP, Yeh YA, Vargas H, Posso H, Terry MB, Gissmann L, Schneider A, Mansukhani M, Rao PH, Murty VV. Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression. Oncogene 2003; 22:3489-99.
19. Mansilla S, Priebe W, Portugal J. Transcriptional changes facilitate mitotic catastrophe in tumour cells that contain functional p53. Eur J Pharmacol 2006; 540:34-45.
20. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59:928-42.
21. The tumor analysis best practices working group: Expression profiling-best practices for data generation and interpretation in clinical trials. Nat Rev Genetics 2004; 5:229-37.
22. Essmann F, Pohlmann S, Gillissen B, Daniel PT, Schulze-Osthoff K, Janicke RU. Irradiation-induced translocation of p53 to mitochondria in the absence of apoptosis. J Biol Chem 2005; 280:37169-77.
23. Bouvard V, Zaitchouk T, Vacher M, Duthu A, Canivet M, Choisy-Rossi C, Nieruchalski M, May E. Tissue and cell-specific expression of the p53-target genes: Bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice. Oncogene 2000; 19:649-60.
24. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002; 1:639-49.
25. Hingorani R, Bi B, Dao T, Bae Y, Matsuzawa A, Crispe IN. CD95/Fas signaling in T lymphocytes induces the cell cycle control protein p21cip-1/WAF-1, which promotes apoptosis. J Immunol 2000; 164:4032-6.
26. Kondo S, Barna BP, Kondo Y, Tanaka Y, Casey G, Liu J, Morimura T, Kaakaji R, Peterson JW, Werbel B, Barnett GH. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene 1996; 13:1279-85.
27. Lindenboim L, Kringel S, Braun T, Borner C, Stein R. Bak but not Bax is essential for BclxS-induced apoptosis. Cell Death Differ 2005; 12:713-23.
28. Bowen JM, Gibson RJ, Keefe DM, Cummins AG. Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 2005; 37:56-62.
29. Chang HJ, Jung KH, Kim DY, Jeong SY, Choi HS, Kim YH, Sohn DK, Yoo BC, Lim SB, Kim DH, Ahn JB, Kim IJ, Kim JM, Yoon WH, Park JG. Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol 2005; 36:364-71.
30. Shehata M, Shehata M, Shehata F, Pater A. Apoptosis effects of Xrel3 c-Rel/Nuclear Factor-kappa B homolog in human cervical cancer cells. Cell Biol Int 2005; 29:429-40.
31. Lee SY, Lee SY, Kandala G, Liou ML, Liou HC, Choi Y. CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity. Proc Natl Acad Sci USA 1996; 93:9699-703.
32. Clarke LE, Bayerl MG, Bruggeman RD, Mauger D, Ioffreda MD, Abou-Elella A, Helm KF. Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin. Am J Surg Pathol 2005; 29:452-9.
33. Duan L, Aoyagi M, Tamaki M, Nakagawa K, Nagashima G, Nagasaka Y, Ohno K, Yamamoto K, Hirakawa K. Sensitization of human malignant glioma cell lines to tumor necrosis factor-induced apoptosis by cisplatin. J Neurooncol 2001; 52:23-36.
34. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436:1186-90.
35. Kim R, Emi M, Tanabe K. Caspase-dependent and -independent cell death pathways after DNA damage (Review). Oncol Rep 2005; 14:595-9.
36. Yanamoto S, Kawasaki G, Yoshitomi I, Mizuno A. Expression of p53R2, newly p53 target in oral normal epithelium, epithelial dysplasia and squamous cell carcinoma. Cancer Lett 2003; 190:233-43.
37. Nakano K, Balint E, Ashcroft M, Vousden KH. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 2000; 19:4283-9.
38. Okumura H, Natsugoe S, Yokomakura N, Kita Y, Matsumoto M, Uchikado Y, Setoyama T, Owaki T, Ishigami S, Aikou T. Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res 2006; 12:3740-5.
39. Liu SS, Cheung AN, Ngan HY. Differential gene expression in cervical cancer cell lines before and after ionizing radiation. Int J Oncol 2003; 22:1091-9.